Great news out of Merck this morning! First Phase 3 readouts from V114,  a 15-valent pneumococcal vaccine that utilizes the carrier protein CRM197 produced via Pfenex Expression Technology! 

$MRK $PFNX #carrierproteins https://t.co/bSsS5VulMi #CRM197 https://t.co/0vpXO0TI4Z